Skip to content

Medical emergency? What to do

Use of Intranasal Flu Vaccine Does Not Show Unexpected Serious Risks

3-RXPublished December 7, 20053 min read

Key points

  • Approximately 2.5 million people received the intranasal influenza vaccine the last 2 flu seasons, and a new study did not identify unexpected serious risks associated with use of this vaccine, according to an article in the December 7 issue of JAMA.
  • Izurieta, M.D., M.P.H., of the Food and Drug Administration, Rockville, Md., and colleagues examined the adverse events reported to the U.S.
  • "Reports to VAERS in the first 2 seasons of LAIV-T use did not identify any unexpected serious risk with this vaccine when used according to approved indications.
  • Annual influenza vaccination is the primary method for protection against influenza illness, according to background information in the article.

Approximately 2.5 million people received the intranasal influenza vaccine the last 2 flu seasons, and a new study did not identify unexpected serious risks associated with use of this vaccine, according to an article in the December 7 issue of JAMA.

Annual influenza vaccination is the primary method for protection against influenza illness, according to background information in the article. Until the 2002-2003 influenza season, the only licensed influenza vaccine in the United States was the inactivated, trivalent (reacting immunologically with three different combining sites [as of antigens or antibodies]) injectable vaccine, with recommendations emphasizing use among individuals for whom influenza is of particular concern. In June 2003, the U.S. Food and Drug Administration (FDA) licensed a trivalent live, attenuated influenza vaccine (LAIV-T [FluMist]) for intranasal use among healthy persons 5 to 49 years of age. Each dose contains live attenuated influenza virus of the 3 strains recommended by the U.S. Public Health Service for the corresponding influenza season. Although the number of vaccinees studied during prelicensure LAIV-T clinical trials was relatively large (20,228), postlicensure administration of the vaccine to much larger populations could reveal new safety issues.

Hector S. Izurieta, M.D., M.P.H., of the Food and Drug Administration, Rockville, Md., and colleagues examined the adverse events reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) during the first 2 influenza seasons (2003-2004, 2004-2005) following LAIV-T licensure to identify new or unexpected adverse events, including rare events.

Approximately 2,500,000 persons received LAIV-T during the first 2 postlicensure seasons. As of August 16, 2005, VAERS received 460 adverse event reports for vaccinations received from August 2003 through July 2005. No fatalities were reported. There were 7 reports of possible anaphylaxis (hypersensitivity reaction to the injection of a substance resulting from prior contact with a substance), 2 reports of Guillain-Barre' syndrome (GBS - a temporary inflammation of the nerves, causing pain, weakness, and paralysis in the extremities), 1 report of Bell palsy (paralysis of the facial muscles), and 8 reports of asthma exacerbation among individuals with a prior asthma history. Events in individuals for whom the vaccine was not indicated accounted for 73 reports (16 percent).

"Reports to VAERS in the first 2 seasons of LAIV-T use did not identify any unexpected serious risk with this vaccine when used according to approved indications. Like many vaccines and other medical products, LAIV-T may rarely cause anaphylaxis. As with other vaccines, LAIV-T could carry the risk of anaphylaxis or other allergic events. Continued monitoring of neurological events, such as GBS, appears warranted. Determination of the risk of secondary transmission of the vaccine virus would require a focused clinical study," the authors write.

"The reports of asthma exacerbations in vaccinees with prior asthma history highlight the potential risks of not following the approved indications and support the need for continued close surveillance for asthma exacerbations following use of this vaccine. The finding of a high proportion of vaccine administration errors and the reports of use among persons for whom this vaccine was not indicated underscore the need for the clinician to follow the package insert indications regarding vaccine administration and patient eligibility," the researchers conclude.

(JAMA.2005; 294:2720-2725. Available pre-embargo to the media at http://www.jamamedia.org)

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underFlu

Keep reading

Flu

Masks, hand sanitizer help halt flu spread

Want to be prepared for a flu pandemic? You may want to stock up on face masks and hand sanitizer, according to a new study. College students living in residency halls who wore the masks for a few hours a day and…

3 min read

Flu

Uzbekistan says closed Kazakh border due to flu

Uzbekistan said on Wednesday it had closed the border with Central Asian neighbour Kazakhstan as part of a seasonal anti-flu quarantine. On Monday, Kazakhstan said Uzbekistan shut the border without any explanations…

1 min read

Flu

Worst case H1N1 may cut UK economy by 4.3 percent

- A severe H1N1 flu pandemic could cost the UK economy 72 billion pounds ($121 billion), British scientists said on Friday, but advised against closing schools even if the current mild pandemic takes a turn for the…

3 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.